Drugs / REGN910-3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01997164 | Nov 2014 → Oct 2015 | diabetic macular edema, wet macular degeneration | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02713204 | Mar 2016 → Oct 2017 | wet macular degeneration | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN910-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02713204 ↗ |
| Route | Intravitreal | “intravitreal (IVT) REGN910-3” NCT01997164 ↗ |